NCT07252908已完成2 期
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQC3721 Inhalation Powder in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 195
- 试验地点
- 46
- 主要终点
- Change of the maximum value of Forced Expiratory Volume in the first second (FEV1)
研究概览
简要总结
To evaluate the efficacy and safety of TQC3721 inhalation powder in patients with moderate to severe Chronic obstructive pulmonary disease (COPD).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Sign the informed consent form before the trial and have a full understanding of the trial content, process, and potential adverse reactions.
- •Be willing and able to adhere to the trial visit schedule and procedures and use the dry powder inhaler correctly.
- •Male and female subjects aged 40 to 80 years (inclusive).
- •Body Mass Index (BMI) within the range of 18-30 kg/m² (inclusive).
- •Subjects have no plans for pregnancy and voluntarily adopt effective contraceptive measures from screening to at least 1 month after the last use of the study drug.
- •12-lead electrocardiogram (ECG) showing: heart rate of 50-100 beats per minute (bpm); corrected QT interval (QTcF) <= 450 msec for males or <= 470 msec for females.
- •Diagnosed with COPD according to the 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, and have had symptoms consistent with COPD for at least 1 year before screening.
- •Have been on stable background inhaled therapy for COPD for at least 4 weeks before screening.
- •Be able to perform acceptable and reproducible pulmonary function tests.
- •At the screening visit (V1 visit), after administration of a bronchodilator (4 puffs of salbutamol), the FEV1/Forced Vital Capacity (FVC) ratio < 0.7, and 30% predicted value <= FEV1 < 80% predicted value.
- •Clinically stable COPD within 4 weeks before the screening visit (V1 visit) and between the V1 visit and V2 visit.
- •Modified Medical Research Council (mMRC) Dyspnea Scale score >= 2 at screening.
- •Meet the concurrent medication restrictions (within the time intervals specified in the protocol) and are expected to maintain the restriction requirements during treatment.
- •Smoking history >= 10 pack-years (pack-year: number of packs per day × number of smoking years; e.g., 1 pack (20 cigarettes) per day for 10 consecutive years, or 10 cigarettes per day for 20 consecutive years).
排除标准
- •Life-threatening COPD history, including admission to the intensive care unit (ICU) and/or requirement for intubation.
- •COPD exacerbation requiring systemic corticosteroid therapy within 3 months before the screening visit (V1 visit) or before the randomization visit (V2 visit).
- •Hospitalization history due to COPD or pneumonia ≥ 1 time within 6 months before screening.
- •Antibiotic treatment for upper and/or lower respiratory tract infections within 6 weeks before screening or before the randomization visit (V3 visit). Note: Subjects with a history of lower respiratory tract infection within 6 weeks cannot be enrolled, but may be rescreened 6 weeks after recovery from the infection.
- •Concurrent other respiratory diseases: α-1 antitrypsin deficiency, primary ciliary dyskinesia, lung cancer; clinically significant active pulmonary infections, pulmonary tuberculosis, bronchiectasis, pulmonary fibrosis, sarcoidosis, pulmonary hypertension, asthma, and other respiratory diseases as assessed by the investigator.
- •Clinically significant abnormalities found on chest computed tomography (CT) that are not caused by COPD and judged by the investigator to have an impact on trial results or patient safety. If there is no chest CT report within 6 months before Visit 1, a chest CT examination must be performed at Visit
- •Previous pulmonary resection or lung volume reduction surgery.
- •Pulmonary rehabilitation therapy (those whose treatment has been stable for 4 weeks before screening and will remain stable during the trial may be enrolled).
- •Receipt of oral corticosteroids or roflumilast for COPD within 3 months before the screening visit (V1 visit), or receipt of oral theophylline and/or theophylline derivatives for COPD within 1 week before the screening visit (V1 visit).
- •Use of non-selective oral beta-blockers.
- •Previous treatment with TQC
- •Patients who received immunotherapy (e.g., azathioprine, cyclophosphamide) within 4 weeks before the screening period.
- •As assessed by the investigator, the patient cannot discontinue the prohibited drugs specified in the protocol during the screening and treatment phases of this study.
- •The patient has a history of currently uncontrolled diseases, including but not limited to endocrine, thyroid, neuropsychiatric, hepatic, gastrointestinal, renal, hematologic, urinary, immunologic, or ophthalmic diseases, which are judged to be clinically significant by the investigator.
- •History or current evidence of clinically significant cardiovascular diseases, defined as any disease that the investigator believes would endanger the patient's safety if participating in the study, or any disease that may affect the efficacy or safety analysis if the disease/condition deteriorates during the study; subjects with any of the following conditions at Visit 1 will be excluded:
- •Myocardial infarction, unstable angina, or stroke within the past 6 months;
- •Unstable or life-threatening arrhythmias requiring intervention within the past 3 months;
- •New York Heart Association (NYHA) Class III-IV heart failure.
- •Unstable or uncontrolled hypertension (systolic blood pressure >= 160 mmHg and diastolic blood pressure >= 100 mmHg after drug control).
- •Patients with poorly controlled type 2 diabetes or fasting blood glucose > 10 mmol/L.
- •Receipt of major surgery (requiring general anesthesia) within 8 weeks before the screening visit (V1 visit), failure to fully recover from the surgery at the time of screening (V1 visit), or planned surgery before the end of the study.
- •History of malignant tumors (cured or uncured) of any organ or system within the past 5 years (excluding non-metastatic cutaneous basal cell or squamous cell carcinoma, or cervical carcinoma in situ that have been cured for more than 5 years before the screening period).
- •Clinically significant abnormal values in safety laboratory tests (hematology, biochemistry, or urinalysis) determined by the investigator at the screening visit (V1 visit), including but not limited to one of the following:
- •Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) > 2 × Upper Limit of Normal (ULN); alkaline phosphatase > 2 × ULN; total bilirubin > 1.5 × ULN;
- •Estimated glomerular filtration rate (eGFR) calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula < 60 mL/min/1.73m².
- •Positive test result for Human Immunodeficiency Virus (HIV) antibody; positive test result for Hepatitis B Surface Antigen (HBsAg) (if HBsAg is positive, Hepatitis B Virus (HBV) DNA testing may be added if necessary; subjects with HBV DNA < Lower Limit of Quantification (LLOQ) need not be excluded); positive Hepatitis C Virus (HCV) antibody with confirmed presence of HCV ribonucleic acid (RNA); positive Treponema Pallidum Particle Agglutination (TPPA) antibody.
- •Intolerance or allergy to salbutamol or other inhaled bronchodilator therapies for COPD.
- •Patients requiring continuous or intermittent oxygen therapy.
- •Female subjects who are pregnant, lactating, or planning to become pregnant during the study enrollment period.
- •Receipt of live attenuated vaccine within 28 days before randomization, receipt of inactivated vaccine within 7 days before randomization, or planned vaccination during the study.
- •History of drug abuse or alcoholism within the past 3 years (consumption of 14 units of alcohol per week: 1 unit = 360 ml of beer, or 45 ml of spirits with 40% alcohol content, or 150 ml of wine).
- •Participation in any drug or medical device clinical trial within 4 weeks or 5 drug half-lives (whichever is longer) before screening.
- •Other conditions deemed unsuitable for study participation by the investigator.
研究组 & 干预措施
750 µg Dosage group
Experimental
750 µg TQC3721 inhalation powder，administered by inhalation，twice a day for 4 weeks.
干预措施: TQC3721 inhalation powder (Drug)
1000 µg Dosage group
Experimental
1000µg TQC3721 inhalation powder，administered by inhalation，twice a day for 4 weeks.
干预措施: TQC3721 inhalation powder (Drug)
Placebo for TQC3721 inhalation powder
Placebo Comparator
Placebo for TQC3721 inhalation powder, administered by inhalation, twice a day for 4 weeks.
干预措施: Placebo for TQC3721 inhalation powder (Drug)
结局指标
主要结局
Change of the maximum value of Forced Expiratory Volume in the first second (FEV1)
时间窗: From baseline to four weeks after treatment
Change of the maximum value of FEV1 was determined from baseline to four weeks after treatment.
Change of the maximum value of Forced Expiratory Volume in the first second (FEV1)
时间窗: From baseline to four weeks after treatment
Change of the maximum value of FEV1 was determined from baseline to four weeks after treatment.
次要结局
- Number of subjects of changes in the peak, trough values of FEV1 and average FEV1 AUC(From baseline to four weeks after treatment)
- Frequency of rescue medication used during the study(From baseline to four weeks after administration)
- Changes in Chronic obstructive pulmonary disease Assessment Test (CAT)(From baseline to four weeks after treatment)
- Peak concentration(From baseline to four weeks after treatment)
- Apparent volume of distribution (Vd/F)(From baseline to four weeks after treatment)
- Apparent clearance (CL/F)(From baseline to four weeks after treatment)
- Half-ife (t1/2)(From baseline to four weeks after treatment)
- Changes in St. George's Respiratory Questionnaire (SGRQ)(From baseline to four weeks after treatment)
- Area under the concentration-time curve from 0 to last observation (AUC 0-t) of TQC3721(From baseline to four weeks after treatment)
- Number of subjects of changes in the peak, trough values of FEV1 and average FEV1 AUC(From baseline to four weeks after treatment)
- Valley concentration(From baseline to four weeks after treatment)
- Adverse Events (AE)(From baseline to safety visit(about 5 weeks after first dosing))
- Frequency of rescue medication used during the study(From baseline to four weeks after administration)
- Changes in Chronic obstructive pulmonary disease Assessment Test (CAT)(From baseline to four weeks after treatment)
- Changes in St. George's Respiratory Questionnaire (SGRQ)(From baseline to four weeks after treatment)
- Peak concentration(From baseline to four weeks after treatment)
- Area under the concentration-time curve from 0 to last observation (AUC 0-t) of TQC3721(From baseline to four weeks after treatment)
- Apparent volume of distribution (Vd/F)(From baseline to four weeks after treatment)
- Apparent clearance (CL/F)(From baseline to four weeks after treatment)
- Half-ife (t1/2)(From baseline to four weeks after treatment)
研究者
研究点 (46)
Loading locations...
相似试验
已完成
2 期
A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic ObstructiveNCT06527144Chia Tai Tianqing Pharmaceutical Group Co., Ltd.240
进行中（未招募）
2 期
A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary DiseaseNCT06707883Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.258
尚未招募
3 期
Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary DiseaseNCT07147946Chia Tai Tianqing Pharmaceutical Group Co., Ltd.666
进行中（未招募）
2 期
评价 TQC2731 注射液在控制不佳的重度哮喘患者中的有效性和安全性。CTR20221541204
已完成
2 期
评价 TQC2731 注射液在控制不佳的重度哮喘患者中的有效性和安全性。CTR20221541204